| parent | Microbiology and Antimicrobial susceptibility | LP343406-7 |
| child | Beta lactamase.usual | LP17265-7 |
| child | Beta lactamase.extended spectrum | LP17264-0 |
| child | Extended-spectrum beta lactamase by ceftazidime to ceftazidime+clavulanate inhibitory concentration ratio | LP232452-5 |
| child | Extended-spectrum beta lactamase by cefotaxime to cefotaxime+clavulanate inhibitory concentration ratio | LP232453-3 |
| child | Extended-spectrum beta lactamase by cefepime to cefepime+clavulanate inhibitory concentration ratio | LP232454-1 |
| child | Metallo beta-lactamase by imipenem to imipenem+EDTA inhibitory concentration ratio | LP232455-8 |
| child | Metallo beta-lactamase by meropenem to meropenem+EDTA inhibitory concentration ratio | LP232456-6 |
| child | AmpC beta-lactamase by cefoTEtan to cefoTEtan+cloxacillin inhibitory concentration ratio | LP232457-4 |
| child | Genetic Antimicrobial Resistance | LP64213-9 |
| child | Susceptibility method | LP32830-9 |
| child | Antivirals | LP31423-4 |
| child | Antitubercular agents | LP31463-0 |
| child | Antiparasitic | LP31445-7 |
| child | Antifungals | LP31435-8 |
| child | Antibiotics | LP31426-7 |
| child | Antibiotics | LP31426-7 |
| child | PANEL.ABXBACT | LP29682-9 |
| PartDisplayName | en-US | ABXBACT |
| DisplayName | en-US | Antibiotic susceptibilities |
LOINC Version: 2.77
FHIR